Dr. S. Chakra Chennubhotla

Bio:

S. Chakra Chennubhotla, PhD, is the Co-Founder and CEO of PredxBio, leading the company’s scientific and technological vision to advance cancer drug discovery through explainable AI and multi-omic spatial analytics. A pioneer in computational and systems pathology, he has spent more than two decades developing machine learning and spatial biology methods that reveal tumor microenvironment architecture and mechanisms of therapeutic response. Before co-founding PredxBio, Dr. Chennubhotla was a Tenured Associate Professor at the University of Pittsburgh, where he served as principal investigator on multiple NIH and NSF programs and raised over $7M in federal research funding focused on tumor heterogeneity, spatial microdomain biology, and computational pathology. He earned his PhD in Computer Science from the University of Toronto. Dr. Chennubhotla is an inventor on multiple issued and pending patents in explainable AI, spatial analytics, and computational pathology. His research has appeared in Science Translational Medicine, Nature Communications, IEEE Transactions on Medical Imaging, and Cancer Research, forming the foundation for PredxBio’s SpaceIQ™ platform, now used by Top-10 pharmaceutical partners.

About PredxBio:

PredxBio is a tissue-based biomarker company building the translational engine that makes spatial biology actionable for pharmaceutical R&D. Using advanced spatial analytics and AI, PredxBio converts tumor biopsy images into decision-grade biomarkers that inform therapeutic decisions across discovery, translational research, and clinical development. PredxBio’s end-to-end platform supports tissue quality control, advanced spatial analysis, biomarker discovery, and translational deployment - operationalizing complex tumor biology into practical insights that help teams reduce risk and accelerate development.